Frequently Asked Questions
The market is segmented based on , By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC) and Anaplastic Thyroid Cancer), Treatment (Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy), Drug Type (Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib and Others), Route of Administration (Oral, Injectable and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others) - Industry Trends and Forecast to 2030.
.
The Global Thyroid Cancer Drug Market size was valued at USD 712.56 USD Million in 2022.
The Global Thyroid Cancer Drug Market is projected to grow at a CAGR of 17.2% during the forecast period of 2023 to 2030.
The major players operating in the market include Mylan N.V., BristolMyers Squibb Company, Teva Pharmaceutical Industries Ltd, Jerome Stevens Pharmaceuticals , Baxter, Abbott, Celgene Corporation, AstraZeneca, GlaxoSmithKline plc, Eisai Co. Ltd, Takeda Pharmaceutical Company Ltd, Biovista, Cytori Therapeutics , Bayer AG, Novartis AG, BioPath Holdings , Vascular Biogenics.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
